Abstract:Objectives To evaluate COVID-19 vaccines in primary prevention against infections and lessen the severity of illness following the most recent outbreak of the SARS-CoV-2 Omicron variant in Shanghai. Data sources Data from 153,544 COVID-19 patients admitted to the Shanghai “Four-Leaf Clover” Fangcang makeshift shelter hospital were collected using a structured electronic questionnaire, which was then merged with electronic medical records of the hospital. For healthy controls, data on vaccination status and other information were obtained from 228 community-based residents, using the same structured electronic questionnaire. Methods To investigate whether inactivated vaccines were effective in protecting against SARS-CoV-2 virus, we estimated the odds ratio (OR) of the vaccination by comparing cases and matched community-based healthy controls. To evaluate the potential benefits of vaccination in lowering the risk of symptomatic infection (vs. asymptomatic), we estimated the relative risk (RR) of symptomatic infections among diagnosed patients. We also applied multivariate stepwise logistic regression analyses to measure the risk of disease severity (symptomatic vs. asymptomatic and moderate/severe vs. mild) in the COVID-19 patient cohort with vaccination status as an independent variable while controlling for potential confounding factors. Results Of the 153,544 COVID-19 patients included in the analysis, the mean age was 41.59 years and 90,830 were males (59.2%). Of the study cohort, 118,124 patients had been vaccinated (76.9%) and 143,225 were asymptomatic patients (93.3%). Of the 10,319 symptomatic patients, 10,031 (97.2%), 281 (2.7%), and 7 (0.1%) experienced mild, moderate, and severe infections, respectively. Hypertension (8.7%) and diabetes (3.0%) accounted for the majority of comorbidities. There is no evidence that the vaccination helped protect from infections (OR = 0.82, p = 0.613). Vaccination, however, offered a small but significant protection against symptomatic infections (RR = 0.92, p < 0.001) and halved the risk of moderate/severe infections (OR = 0.48, 95% CI: 0.37–0.61). Older age (≥60 years) and malignant tumors were significantly associated with moderate/severe infections. Conclusion Inactivated COVID-19 vaccines helped provide small but significant protection against symptomatic infections and halved the risk of moderate/severe illness among symptomatic patients. The vaccination was not effective in blocking the SARS-CoV-2 Omicron Variant community spread.

Vaccination increased host antiviral gene expression and reduced COVID-19 severity during the Omicron variant outbreak in Fuyang City, China

Omicron COVID-19 Variant Outcomes and Vaccination in Non-Severe and Non-Critical Patients at Admission

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai

Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai

Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China

Vaccination Effects on Post-Infection Outcomes in the Omicron BA.2 Outbreak in Shanghai

Viral and Host Factors Related to the Clinical Outcome of COVID-19

EPH100 Evaluation of COVID-19 Vaccines in Primary Prevention Against Infections and Reduction in Severity of Illness Following the Outbreak of Sars-Cov-2 Omicron Variant in Shanghai

Host Protection Against Omicron BA.2.2 Sublineages by Prior Vaccination in Spring 2022 COVID-19 Outbreak in Shanghai

Viral and host factors related to the clinic outcome of the SARS CoV 2 infection

Clinical Progression and Outcome of Hospitalized Patients Infected with SARS-CoV-2 Omicron Variant in Shanghai, China

Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China

Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants

Clinical Characteristics and Outcome of Patients with Sars-Cov-2 Omicron Variant in Shanghai: A Single Center, Retrospective, Observational Study

Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China

Vaccination Shapes Within-Host SARS-CoV-2 Diversity of Omicron BA.2.2 Breakthrough Infection

Nasopharyngeal Local Transcriptional Profile Upon SARS-CoV-2 Omicron BA.2.2 Breakthrough Infection

Vaccination status and disease severity of COVID-19 in different phases of the pandemic

Clinical characteristics of 1139 mild cases of the SARS‐CoV‐2 Omicron variant infected patients in Shanghai

Reduced Clinical Severity During 2022 Shanghai Spring Epidemic of SARS-CoV-2 Omicron BA.2 Variant Infection-an Integrated Account of Virus Pathogenicity and Vaccination Effectiveness.